BioDuro, a globally trusted contract research, development, and manufacturing organization (CRDMO), has announced a strategic partnership with Atombeat Inc., a leader in AI-powered drug discovery. Together, they aim to launch an end-to-end platform for accelerated peptide drug discovery and development.

This collaboration merges Atombeat’s cutting-edge in silico modeling and AI-driven design capabilities with BioDuro’s strengths in discovery chemistry, biology, DMPK, and high-throughput peptide manufacturing. The integrated platform is designed to rapidly develop high-quality cyclic peptides across multiple therapeutic areas — improving speed, efficiency, and cost-effectiveness from molecular design to preclinical candidates.

Atombeat’s proprietary Hermite software and RiDYMO platform, powered by technologies such as Reinforced Dynamics and Uni-QSAR, enable rapid screening of over one trillion peptide compounds derived from more than 1,000 amino acids. This virtual exploration identifies and prioritizes drug candidates based on critical developability metrics like membrane permeability — all before lab testing begins.

Once promising compounds are selected, BioDuro’s peptide synthesis platform enables parallel production of hundreds of high-purity peptides within one week, without the need for purification. Integrated biology assays then validate these compounds, significantly accelerating timelines and reducing R&D costs.

“This partnership strengthens our peptide innovation capabilities,” said Dr. Armin Spura, CEO, BioDuro. “Combining Atombeat’s AI tools with our manufacturing scale will help us deliver smarter and faster solutions to global clients.”

Dr. Dongdong Wang, Co-founder of Atombeat, added, “BioDuro’s synthesis and testing capabilities align perfectly with our AI-first approach. Together, we aim to redefine peptide drug discovery through an intelligent, integrated workflow.”

BioDuro, backed by Advent International, operates across 7 global sites and employs over 2,000 professionals. Atombeat is led by elite computational and medicinal chemists, focused on democratizing advanced drug discovery tools.